Business Wire

NEDGROUP-INVESTMENTS

10.5.2023 09:50:27 CEST | Business Wire | Press release

Share
Nedgroup Investments expands boutique advantage range, onboards David Roberts and Alex Ralph to launch fixed income boutique

Nedgroup Investments, a global asset manager with over $20bn AUM, is launching an in-house multi-boutique platform which will feature a growing range of active investment strategies characterised by deep alignment of client and fund manager interests.

Tom Caddick, Managing Director of Nedgroup Investments (International) commented: “It's harder for boutiques to set up now because of the onerous regulatory requirements and the difficulty of raising sufficient capital. We want to facilitate start-up boutiques to better serve the needs of our clients and provide a wider range of investment opportunity. We can create a more diverse fund management sector for the benefit of the end investor. I’m thrilled to launch our innovative structure with two conviction managers I have known and respected for over 20 years.”

Fixed-income veterans David Roberts and Alex Ralph will run an active global bond fund as the first launch of these in-house managed strategies.

Roberts commented: “I have returned to active investing because market conditions are too compelling to ignore. I have always had conviction to invest when risk and reward are in the client’s favour. After a couple of years when return expectations were negative, we are back in an environment where fixed income is once again a diversifier, a very attractive alternative to equities. The old normal.”

Ralph adds: “Many have been waiting a decade for this type of entry point and the possibility of earning significant, long term positive returns without the need to venture into the dark, equity-like corners of the bond market.”

Addressing the attractions of the firm, Roberts commented: “Nedgroup Investment’s has a long-standing belief in the benefits to investors of boutique models and they share my client-centric approach. Those were the deciding factors for me. It is rare these days to find a business willing to innovate and support a boutique from inception.”

Apiramy Jeyarajah, who joined Nedgroup Investments as Chief Commercial Officer in April 2023, added: “Starting an investment boutique is increasingly difficult. We are excited to offer clients access to compelling teams, complementing the existing boutiques on our platform. Nurturing opportunities with experienced fund managers will help investors benefit from increased choice and a competitive edge.”

About Nedgroup Investments

Nedgroup Investments is a global asset manager with over $20 billion AUM with its international business led from London and global headquarters in Cape Town. Nedgroup Investments is known for its award winning ‘Best of Breed’ partnership model with leading boutique managers in London, Los Angeles, New York and Sydney, offering investors access to the world’s best managers and their funds.

The Nedgroup Investments Boutique Advantage Philosophy

Nedgroup Investments’ fundamental belief is that the best performing investment funds are run by managers that are autonomous, focused and have a concentrated alignment of interests with the unit-holders of their fund.

Fund Range

Nedgroup Investments has two fund ranges – Nedgroup Investments Funds Plc (launched in November 2008) and Nedgroup Investments Multifunds Plc (launched in August 2011).

About David Roberts

David Roberts is a fixed income investor with over 30 years’ experience. He is known for his skin in the game investment style and was previously head of fixed income at Liontrust until early 2022. Previously, he was a fund manager with Aegon Asset Management (formerly Kames Capital) where he was also co-head of fixed income and worked for 14 years. Prior to that, he held roles at Britannia Investment Managers and Lloyds Bank.

About Alex Ralph

Alex Ralph is a highly respected fixed-income fund manager with over two decades of experience in the industry. She is widely recognized for her strong track record of success and is considered one of the leading fixed-income investors of her generation. Alex was most recently a partner at Artemis Investment Management where she helped set up the bond desk launching the Strategic bond fund in 2005. In 2014, she was also appointed lead fund manager on the Artemis high income fund. The desk managed some £3 billion in credit by the end of her tenure at Artemis. Alex holds a BSc in Economics from London School of Economics and is a CFA Charter holder.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006145/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye